BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 326 filers reported holding BIO-TECHNE CORP in Q4 2018. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,960 | -3.2% | 222,422 | +10.1% | 0.04% | -48.1% |
| Q2 2023 | $16,496 | +26.6% | 202,077 | +15.1% | 0.08% | +17.9% |
| Q1 2023 | $13,026 | +2.8% | 175,579 | +14.9% | 0.07% | -2.9% |
| Q4 2022 | $12,669 | -99.9% | 152,856 | +300.0% | 0.07% | +9.5% |
| Q3 2022 | $10,853,000 | -18.1% | 38,214 | 0.0% | 0.06% | -13.7% |
| Q2 2022 | $13,247,000 | -19.9% | 38,214 | 0.0% | 0.07% | -2.7% |
| Q1 2022 | $16,548,000 | -19.8% | 38,214 | -4.1% | 0.08% | -10.7% |
| Q4 2021 | $20,621,000 | +2.4% | 39,859 | -4.1% | 0.08% | -5.6% |
| Q3 2021 | $20,147,000 | +4.2% | 41,577 | -3.1% | 0.09% | +6.0% |
| Q2 2021 | $19,327,000 | -49.4% | 42,923 | -57.1% | 0.08% | -53.1% |
| Q1 2021 | $38,224,000 | +33.6% | 100,082 | +11.1% | 0.18% | +28.8% |
| Q4 2020 | $28,608,000 | +44.0% | 90,091 | +12.4% | 0.14% | +32.4% |
| Q3 2020 | $19,862,000 | -7.9% | 80,177 | -1.8% | 0.10% | -14.6% |
| Q2 2020 | $21,559,000 | +39.3% | 81,643 | 0.0% | 0.12% | +13.9% |
| Q1 2020 | $15,481,000 | -13.4% | 81,643 | +0.2% | 0.11% | +6.9% |
| Q4 2019 | $17,880,000 | +12.2% | 81,455 | 0.0% | 0.10% | +4.1% |
| Q3 2019 | $15,938,000 | -6.2% | 81,455 | 0.0% | 0.10% | -6.7% |
| Q2 2019 | $16,983,000 | +0.3% | 81,455 | -4.5% | 0.10% | -3.7% |
| Q1 2019 | $16,927,000 | -8.7% | 85,253 | -33.5% | 0.11% | -18.8% |
| Q4 2018 | $18,540,000 | -29.1% | 128,109 | -0.0% | 0.13% | -15.8% |
| Q3 2018 | $26,152,000 | +38.0% | 128,125 | -0.0% | 0.16% | +28.5% |
| Q2 2018 | $18,957,000 | -2.1% | 128,132 | -0.0% | 0.12% | -4.7% |
| Q1 2018 | $19,356,000 | -8.6% | 128,153 | -21.6% | 0.13% | -4.4% |
| Q4 2017 | $21,178,000 | +14.7% | 163,475 | +7.0% | 0.14% | +1.5% |
| Q3 2017 | $18,465,000 | +20.2% | 152,739 | +16.8% | 0.13% | +17.7% |
| Q2 2017 | $15,362,000 | +1852.0% | 130,739 | +1588.7% | 0.11% | +1783.3% |
| Q1 2017 | $787,000 | -1.4% | 7,742 | -0.2% | 0.01% | 0.0% |
| Q4 2016 | $798,000 | -6.1% | 7,757 | -0.1% | 0.01% | -14.3% |
| Q3 2016 | $850,000 | -2.9% | 7,761 | +0.1% | 0.01% | 0.0% |
| Q2 2016 | $875,000 | +19.2% | 7,757 | -0.2% | 0.01% | +16.7% |
| Q1 2016 | $734,000 | +8.4% | 7,769 | +3.3% | 0.01% | 0.0% |
| Q4 2015 | $677,000 | -2.6% | 7,524 | +0.1% | 0.01% | 0.0% |
| Q3 2015 | $695,000 | -6.2% | 7,514 | -0.2% | 0.01% | 0.0% |
| Q2 2015 | $741,000 | -2.0% | 7,527 | -0.2% | 0.01% | 0.0% |
| Q1 2015 | $756,000 | +8.9% | 7,543 | +0.4% | 0.01% | 0.0% |
| Q4 2014 | $694,000 | – | 7,513 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |